Amira Announces AM103 and AM803 Patent Grant in the United Kingdom

Patent Covers FLAP (5-Lipoxygenase Activating Protein) Inhibitor Licensed to GSK

SAN DIEGO, July 13, 2010 - Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual
Property Office has granted patent number GB2431927, titled, "5-Lipoxygenase
Activating Protein (FLAP) Inhibitors," which includes coverage of Amira's
AM103 and AM803 FLAP inhibitors for the treatment of respiratory disorders.

In January 2008, Amira and GlaxoSmithKline (GSK) entered into a worldwide
exclusive agreement allowing GSK to develop, manufacture and commercialize
specified FLAP inhibitors for the treatment of respiratory and cardiovascular
disease. AM803 was added to the license agreement later in 2008. GSK is
currently conducting Phase 2 clinical trials in respiratory disorders with an
Amira-licensed FLAP inhibitor.

"Amira continues to be successful in obtaining patent coverage for
compounds being advanced in clinical trials," said John Hutchinson, Ph.D.,
Vice President of Chemistry. "This patent covering both AM103 and AM803 is
the third issued this year, following two patents related to our DP2 receptor
antagonists granted by the United Kingdom." Bob Baltera, Chief Executive
Officer of Amira, added, "This patent relates to some of the first compounds
developed by Amira. It reflects our ongoing objective to secure strong patent
protection around each of our development programs."

The newly granted claims cover novel inhibitors of the FLAP protein. The
patent also discloses uses of FLAP inhibitors for the treatment of
inflammatory diseases such as asthma, cardiovascular disease, dermatological
disorders and ocular diseases.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is
a small molecule pharmaceutical company focused on the discovery and early
development of new drugs to treat inflammatory disease. Our discovery team is
building on unparalleled insights into bioactive lipid pathways and complex
signaling processes controlling many conditions including asthma, chronic
obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira
has a partnership with GlaxoSmithKline for the development of FLAP
(5-lipoxygenase activating protein) inhibitors in respiratory and
cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the
ingenuity and energy of a small company, creating an environment for
efficient development of novel compounds and effective pre-clinical and
clinical program decisions. Its scientific founders have successfully worked
together for more than a decade and were pivotal in the discovery of a number
of inflammatory drugs, including Singulair(R). The drug hunters at Amira are
now actively leveraging their history of success to create high-value
compounds for the future. For more information, visit
www.amirapharm.com.

Ian Stone of Russo Partners, +1-619-528-2220, ian.stone at russopartnersllc.com, for Amira Pharmaceuticals